Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.36 |
| ▸ | MTOR | P42345 | 6/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | OXTR | P30559 | 1/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.32 |
| ▸ | S100A9 | P06702 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30847991 | 1.00 | PIK3CA (0.36) | PIK3CAMTORRXRAGRIN1GRIN2B | |
| SCHEMBL30847993 | 0.89 | SLC40A1 (0.38) | RXRAGRIN1GRIN2BSCN9ASYK | |
| SCHEMBL27132348 | 0.89 | SLC40A1 (0.38) | RXRAGRIN1GRIN2BSCN9ASYK | |
| SCHEMBL30848073 | 0.86 | RXRA (0.38) | RXRAGRIN1GRIN2BSCN9AGRM2 | |
| SCHEMBL27133692 | 0.86 | RXRA (0.38) | RXRAGRIN1GRIN2BSCN9AGRM2 | |
| SCHEMBL30848042 | 0.85 | RXRA (0.36) | RXRAGRIN1GRIN2BSCN9AAR | |
| SCHEMBL27132783 | 0.85 | RXRA (0.36) | RXRAGRIN1GRIN2BSCN9AAR | |
| SCHEMBL27133721 | 0.85 | PIK3CA (0.39) | PIK3CAMTORSCN9AOXTRAVPR1A | |
| SCHEMBL30848281 | 0.84 | SLC40A1 (0.40) | PIK3CAMTORRXRAGRIN1GRIN2B | |
| SCHEMBL27132781 | 0.84 | SLC40A1 (0.40) | PIK3CAMTORRXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | PIK3CA 1008/4885MTOR 70/4885RXRA 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.